Journals / International Journal of Health Services Research and Policy / 2020 / Cilt: 5 - Sayı: 3

INVESTIGATION OF SFLT-1 AND VEGF EXPRESSION IN NORMOTENSIVE AND PREECLAMPTIC PLACENTA. AN IMMUNOHISTOCHEMICAL STUDY

Pages
206–214
Publication Date
2020-12-25
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Overall, this study demonstrates, imbalance between VEGF and sFlt-1 is one of the major reason of endothelial dysfunction in preeclamptic placenta.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: The pathogenesis of preeclampsia is still not clear, but endothelial dysfunction believed to be one of the most encountered problems during placenta development in preeclamptic patients.
📊
Key Findings & Data:Both vascular endothelial growth factor (VEGF) and its antagonist, soluble Fms-Like tyrosine kinase-1 (sFlt-1), have roles in vascular function.
💡
Conclusion & Impact:Overall, this study demonstrates, imbalance between VEGF and sFlt-1 is one of the major reason of endothelial dysfunction in preeclamptic placenta.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:preeclampsia · placenta · immunohistochemistry

Abstract

Objectives: The pathogenesis of preeclampsia is still not clear, but endothelial dysfunction believed to be one of the most encountered problems during placenta development in preeclamptic patients. Both vascular endothelial growth factor (VEGF) and its antagonist, soluble Fms-Like tyrosine kinase-1 (sFlt-1), have roles in vascular function. In this study, we have investigated immunohistochemical expression of VEGF and sFlt-1 in term placenta of normotensive and preeclampsia patients. Methods: Totally twenty term placentas were obtained from pregnant women of which 10 preeclampsia patient and 10 normotensive. Placentas were dissected and tissue samples were subjected to routine tissue processing protocol, then embedded in paraffin blocks. Serial sections were obtained from paraffin blocks and stained with H&E and PAS for routine histopathology. VEGF and sFlt-1 immunohistochemistry was performed to the sections. Results: When compared to control group, severe pathological changes were observed in preeclamptic placentas. Increase in number of syncytial knots and intervillous bridges, hemorrhage in interstitium, dilatation and congestion in villous capillaries, increase in fibrin accumulation in villus stroma, and increase in thickening of basement membrane were very clear. VEGF expression was significantly higher in normotensive placentas compared to preeclamptic. On the other hand, sFlt-1 expression was significantly increased in preeclamptic placentas. Conclusions: When the VEGF and sFlt-1 expression was considered, higher expression of sFlt-1 at preeclampsia, but decrease in VEGF expression, might be related to endothelial dysfunction in preeclampsia. Overall, this study demonstrates, imbalance between VEGF and sFlt-1 is one of the major reason of endothelial dysfunction in preeclamptic placenta.

🔖

Cite This Article

SAHİN, F., AKKUŞ, M., ŞEKER, U., SOKER, S., GOKALP-OZKORKMAZ, E., AĞAÇAYAK, E., AŞIR, F. (2020). INVESTIGATION OF SFLT-1 AND VEGF EXPRESSION IN NORMOTENSIVE AND PREECLAMPTIC PLACENTA. AN IMMUNOHISTOCHEMICAL STUDY. International Journal of Health Services Research and Policy, Cilt: 5 - Sayı: 3, 206–214. https://ajindex.com/articles/767434

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. J. Roberts and D. W. Cooper, "Pathogenesis and genetics of pre-eclampsia," The Lancet, vol. 357, no. 9249, pp. 53-56, 2001
  2. U. Högberg, "The World Health Report 2005:``Make every mother and child count''—including Africans," ed: Sage Publications Sage UK: London, England, 2005
  3. J. J. Walker, "Pre-eclampsia," The Lancet, vol. 356, no. 9237, pp. 1260-1265, 2000
  4. W. P. Mutter and S. A. Karumanchi, "Molecular mechanisms of preeclampsia," Microvascular research, vol. 75, no. 1, pp. 1-8, 2008
  5. J. Zhang et al., "Blood pressure dynamics during pregnancy and spontaneous preterm birth," American journal of obstetrics and gynecology, vol. 197, no. 2, pp. 162. e1-162. e6, 2007
  6. E. Teran, A. Calle, and C. Escudero, "Endothelial dysfunction and preeclampsia," American journal of hypertension, vol. 20, no. 9, pp. 1026-1027, 2007
  7. S. E. Maynard et al., "Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia," The Journal of clinical investigation, vol. 111, no. 5, pp. 649-658, 2003
  8. A. C. Palei, F. T. Spradley, J. P. Warrington, E. M. George, and J. P. Granger, "Pathophysiology of hypertension in pre‐eclampsia: a lesson in integrative physiology," Acta physiologica, vol. 208, no. 3, pp. 224-233, 2013
  9. J. P. Granger, B. T. Alexander, M. T. Llinas, W. A. Bennett, and R. A. Khalil, "Pathophysiology of hypertension during preeclampsia linking placental ischemia with endothelial dysfunction," Hypertension, vol. 38, no. 3, pp. 718-722, 2001
  10. R. Dechend and F. C. Luft, "Angiogenesis factors and preeclampsia," Nature medicine, vol. 14, no. 11, pp. 1187-1188, 2008
  11. N. A. Ibrahim and D. M. Khaled, "Histological and immunohistochemical study on human placental tissue in normal pregnancy and preeclampsia," Cell Biol, vol. 2, pp. 72-80, 2014
  12. P. Navbir, N. Alka, and G. Antima, "Histological changes in placentae in pregnancies complicated by preeclampsia and eclampsia and correlation with fetal outcome," Int J Pharm Bio Sci, vol. 3, no. 2, pp. 551-60, 2012
  13. R. R. Corrêa et al., "Placental morphometrical and histopathology changes in the different clinical presentations of hypertensive syndromes in pregnancy," Archives of Gynecology and Obstetrics, vol. 277, no. 3, pp. 201-206, 2008
  14. I. de Luca Brunori et al., "Placental barrier breakage in preeclampsia: ultrastructural evidence," European Journal of Obstetrics & Gynecology and Reprod